Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.41, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.57, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company has no cash and equivalents, and its operating cash flow is negative at -232.46 million CNY, which may raise concerns about its ability to fund operations without external financing.

In terms of profitability, the company's return on equity (ROE) is 7.89%, and its return on assets (ROA) is 3.53%. These figures are below the typical benchmarks for the pharmaceutical industry, indicating that the company is not generating returns as efficiently as its peers. The gross profit margin is 16.15%, and the operating margin is 4.67%, both of which are relatively low compared to industry standards.

The company's revenue is primarily concentrated in its domestic market, with no significant international revenue disclosed. This lack of geographic diversification may expose the company to higher risks associated with local economic and regulatory changes. The company operates in a single business segment, which is typical for many pharmaceutical firms, but it also means that there is no diversification benefit from multiple revenue streams.

The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current fiscal year. The company's revenue for the latest period was 7.77 billion CNY, and there is no indication of a substantial increase in the near term. The company's capital expenditure for the period was -1.24 billion CNY, suggesting a reduction in investment in new projects or facilities.

The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which could indicate potential liquidity constraints. The company's free cash flow is positive at 1.05 billion CNY, which is a positive sign for its ability to fund operations and potentially return value to shareholders.

Recent events and disclosures do not indicate any major changes in the company's operations or financial strategy. The company's stock has a mean price target of 19.17 CNY, with a median price target of 20.00 CNY, suggesting that analysts have a generally positive outlook on the stock. The mean recommendation from analysts is 2.67, which is a "buy" rating, indicating that the company is considered a favorable investment opportunity.